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Summary Points: 
 The overdose risk information (ORION) tool has been designed with the aim of being easy-to 
use and informative to both patients and clinicians in various clinical settings. 
 The ORION tool went through risk estimation processes using Delphi methods 
 The ORION tool utilised state of the art design systems to help engage the user 
  A pilot implementation of the ORION tool was conducted in the four countries to assess the 
feasibility of implementing the tool across various clinical settings.  
 
Abstract 
Background and Objective: The application of e-health technology to the field of substance 
use disorders is at a relatively early stage, and methodological quality is still variable. Few 
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have explored the extent of utilization of communication technology in exploring risk 
perception by patients enrolled in substance abuse services.  
The Overdose RIsk InfOrmatioN (ORION) project is a European Commission funded 
programme, aimed to develop and pilot an e-health psycho-educational tool to provide 
information to drug using individuals about the risks of suffering a drug overdose.  
Methods: In this article we report on phase 1 (risk estimation), phase 2 (design), and phase 
3 (feasibility) of the ORION project. 
Results: The development of ORION e-health tool underlined the importance of an 
evidence-based intervention aimed in obtaining reliable evaluation of risk. The ORION tool 
supported a decision making process aimed at influencing the substance users’ self-efficacy 
and the degree to which the substance users’ understand risk factors. Therefore its 
innovative power consisted in translating risks combination into a clear estimation for the 
user who will then appear more likely to be interested in his/her risk perception. 
Conclusion: Exploratory field testing and validation confirmed the next stage of evaluation, 
namely, collection of routine patient samples in study clinics. The associations between risk 
perception of overdose, engagement with the ORION tool and willingness to alter overdose 
risk factors, in a clinical setting across various EU member states will further confirm the 
ORION tool’s generalisability and effectiveness. 
 
Keywords: Risk, Opioids, Decision making 
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Introduction 
Illicit drug overdose is a leading cause of premature death and morbidity among opioid 
users [1]. Several systematic reviews have identified conditions that increase the risk of 
drug-related deaths [2-8]. The severity of dependence, polysubstance use, polypharmacy, 
history of suicide attempt, length of drug using career, number of network members who 
inject drugs and homelessness, all have been reported as important risk factors for fatal 
overdoses [9-14]. 
 
The perception of risk is a cognitive and learning process through which variably individuals 
assign positive or negative properties to a determined object or event, potentially exposing 
them to high risk behaviour [15]. However ‘risk perception is not a unified phenomenon but 
one that is conditional on social status, social rules and rewards within particular contexts’ 
[16]. Usually it is conceptualized in terms of personal vulnerability to the health effects of 
their risky behaviour, optimistic bias (inaccurate estimation of lower personal risk in 
comparison to other counterparts) and precaution effectiveness (believing that engaging in 
precautionary behaviour will be beneficial to their health) [17]. 
 
Since health behaviour models are mostly based on decision theories, risk behaviours are 
assumed to represent conscious actions. However, the relationship between risk perception 
and risky behaviour is inconclusive. Meta-analysis by Harrison et al [18] showed that the 
average correlation between risk perception measures and health behaviours never 
exceeded 0.22 [19, 20]. Knowledge itself of being engaged in risky activities may lead to a 
heightened sense of personal risk but at the same time, a reduced sense of vulnerability, 
contributing to greater risk taking [21]. Risk perception may increase with maturation due to 
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(1) a decrease in sensation seeking and decline in danger invulnerability [22] (2) a greater 
exposure to health problems, lower optimism about avoiding harm and misfortune [23] and 
(c) a higher sense of health responsibility related to the change from the present-hedonistic 
perspective toward a more future orientation [24]. 
 
The adoption of a broader public health approach concerned with risk, rather than a clinical 
focus restricted to consumption or the treatment of dependence, has been extremely 
influential among adult drug using population [25]. Secondary prevention objectives among 
substance users may either be specific to risk behaviours (e.g. reduction in current drug 
consumption, prevention of injecting, take home naloxone), or generic (addressing the 
totality of a young person’s relationship to drugs). A systematic review on the effectiveness 
of take-home naloxone [26] identified only one interrupted time-series study, showing ‘that 
overall educational and training interventions complemented by take-home naloxone would 
decrease overdose-related mortality’ [27]. However literature exploring these same 
educational and training interventions shows poor evidence in sustaining a reduction in 
mortality rates in the long term [28]. At most, they can have a short-term effect in raising 
awareness and changing the way these phenomena are understood but not necessarily 
changing behaviours [29]. Indeed, assessment of short-term intervention effect on risk 
perception may be the logical first step in the evaluation of intervention efficacy [30]. 
The application of e-health technology to the field of substance use is at a relatively early 
stage, and methodological quality is still variable [31, 32]. A number of researchers have 
explored the role that information and communication technologies may play in the delivery 
of evidence-based behavioural interventions in improving the effectiveness, cost-
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effectiveness, and reach of efforts to assess, treat, and support the recovery management 
of substance use disorders and other risk behaviours [32-36]. Few have explored the extent 
of utilization of communication technology by patients enrolled in substance abuse services 
[37]. Overall most decision aids did not explore risk perception and in some there are 
concerns about the completeness, balance and accuracy of information included [38]. 
 
Helpful evidence come from the chronic disease conditions field, with many attempts to 
develop tools to estimate risks of complex behaviours [39-41]. For example, a Cochrane 
review on decision making tools in the field of oncology has established that there is strong 
evidence that personalised risk estimates incorporated within communication interventions 
for screening programmes enhance informed choices [42].  
The  Overdose RIsk InfOrmatioN (ORION) project, a European Commission funded 
programme, aimed to develop and pilot an e-health psycho-educational tool to provide 
information to drug using individuals about the risks of suffering a drug overdose [43]. This 
overdose risk information (ORION) tool has therefore been designed with the aim of being 
easy-to use and informative to both patients and clinicians in various clinical settings. In this 
article we report on phase 1 (risk estimation), phase 2 (design), and phase 3 (feasibility) of 
the ORION tool 
 
Methods 
Setting: Recruitment occurred with the same three month period in treatment centres 
across four European countries: UK, Germany, Italy and Denmark, in both in- and out-
patient healthcare settings (NHS Fife Addiction Services in Scotland, Essen LVR-Hospital in 
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Germany; Monza Regional Addiction Service in Italy and Aarhus University Hospital in 
Denmark).  
Participants: A pragmatic opportunistic approach was taken to recruit a number of 
consented patients from the participating centres balancing the tight timeframe 
workpackages provided by our EU funders and the need to apply through different research 
and ethical governance approval processes. We initially recruited 10 patients from one 
centre in the UK (NHS Fife Addiction Service) and their key workers to ‘test’ the feasibility of 
ORION template tool before introducing the finalised tool to patients aged between 18 and 
55 years old who were seeking treatment for their opioid dependence attending the four 
identified centres. Individuals with a current history of psychosis, confirmed learning 
disabilities, acute intoxication and patients who were unable to give informed consent for 
other reasons were excluded from this study (Table 1). All staff involved in the feasibility 
stage of this study were addiction nurses trained in both mental health and addictions and 
working as key workers to individuals suffering from dependency issues. 
 
INSERT TABLE 1 here 
 
Study Design: The design of the ORION project utilised a Delphi consensus process known as 
the International Patient Decision Aids Standards (IPDAS) Collaboration [44] ,which 
recommends that one needs to develop two critical activities to produce workable on-line 
decision tools; (1) prototype field-testing and (2) exploratory field-testing [45, 46]. 
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Statistical analyses  
Phase 1: Risk estimation modelling. Overdose risk factors initially identified  through a 
systematic review as ‘individual', ‘situational’ and /or ‘organisational’ risk factors were sub-
categorised into: drug use, circumstances of overdose, experience of treatment, psychiatric 
and physical health problems, social contexts, consequences of intervening, treatment and 
use of emergency service.  The model shows a point estimate of relative risk expressed as a 
percentage. 
 
 
The relative risk percentage was obtained using the follow steps. In order to develop the 
mortality risk (Table 2): 
1. For eight age-gender combinations the annual mortality rates in England and Wales 
general population were obtained from the Office of National Statistics [47]. A table 
with 4,096 rows was constructed. This corresponds to 9 (risk/protective) factors each 
with 2 levels (yes/no) x gender (male/female) x 4 age bands. 
2. For each row, the estimated relative risk ratio (i.e. 1 equals no difference compared 
to general population) of overdose was inputted. 
3. If a participant had no risk factors, the baseline mortality rate was multiplied by a 
factor of 1.1, to allow for the fact that even with no risk factors drug users are likely 
to have a higher mortality rate. 
4. The percentage relative risk was calculated by dividing each risk profile’s risk by the 
baseline population risk. 
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5. As the range of the relative risk percentage was 10 to 2980, it was standardized to a 
scale ranging from 0-100. 
 
Thus for a female aged 15-24 with one risk factor (mixing drugs), the annual mortality risk is 
1.63 per 1,000 population (the baseline risk is 0.295 per 1,000 population). Dividing the 
annual mortality risk by the baseline risk and converting it to a percentage, yields a figure of 
450%. Converting this to a risk scale of 0-100 (based on the spectrum of relative risk ranging 
from 10-2980%) gives a figure of 15.1%. 
 
In summary, the risk score shown is a relative measure ranging from non-users to 
individuals with all nine risk factors for potential overdose present. 
 
INSERT TABLE 2 here 
 
Phase 2: Interface and system design: The visual design and computer programming of the 
software was undertaken by experts from Keele University, and was designed to reside on a 
PC laptop for flexible utilisation in various clinical settings. The initial prototype was 
approved by experts at St Andrews University and ensured quality control to the actual 
coding, programming and platform compatibility of the interface. 
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Phase 3: Feasibility of the ORION eHealth tool: 
Service users and staff from NHS Fife Addiction Services, Scotland tested the validation of 
the prototype to ensure the delivered product was functioning and user friendly (prototype 
field testing). This group were also asked to give feedback aimed at verifying users’ 
comprehensibility of this eHealth tool. The tool was subsequently tested on a wider patient 
population attending the four health care addiction centres (exploratory field testing). 
Mechanical issues (e.g. ability of patients in another country to open the computer, 
switching it on, logging in, opening the software and follow instructions) and interpretative 
issues (e.g. understanding what is asked of them, language issues, ability to follow the 
screen shots and participating in risk perception and changes as per instructions) were 
considered as the ORION study’s criteria of validation. 
Research governance: Formal ethics and management approvals were secured in all four 
clinical centres for the ORION protocol.  
 
Results: Development of the Overdose Risk Information (ORION) software programme 
Phase 1 – Risk estimation 
A fundamental step for development of a e-health intervention tool is building consensus 
among experts with the aim of identifying, through a literature review, factors influencing 
overdose risk (predictors), referring to individual, situational and organizational categories.  
 
The first consideration for the ORION project was the specification of benefit and risk in 
relation to overdose prevention. Benefit and risk were defined as reduction or increase 
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consecutively in behaviour that will result or not in a subsequent fatal or non fatal overdose. 
Our model shows final point estimates of risk in percentages.   
 
Seven aggregate risk factors were identified for inclusion, either on the basis of being within 
the control of the individual or particularly relevant to the specific clinical settings. The 
aggregate risk factors were: mixing drugs, no intervention, mental health difficulties, not 
receiving treatment, injecting behaviour, previous overdoses and recent (2 weeks) release 
from prison (Table 3). 
 
INSERT TABLE 3 here 
 
Phase 2: Interface and system design 
A master document was compiled in the English language, which was then translated and 
back translated into German, Italian, and Danish. The final software included visually 
engaging and user friendly screens. The screen shots, once ORION tool was opened, 
involved: 
1. Welcome Screen – describing the programme and legal disclaimer regarding 
overdose risk estimation. 
2. Demographic Information – prompting the users to enter their participant number, 
as well as gender and age band. 
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3. Initial Risk Assessment Questions – nine risk assessment questions with drop down 
menus allowing the users to indicate whether or not this particular risk factor applies 
to them (Figure 1). 
4. First Overdose Risk Feedback – displayed by a black marker placed along a horizontal 
bar ranging from low to high overdose risk, which was placed against the overdose 
risk of a non drug user for comparison. The risk is shown on a scale of 0-100 where 0 
= lowest risk and 100 = highest risk of suffering a drugs overdose (Figure 2).  
5. Option to Change Answers and Review of Modified Risk – participants were given the 
option to review their answers and visually inspect how different answers to the 
overdose risk questions are reflected in changes in the overdose risk feedback 
graphic (Figure 3).  
6. Debriefing Screen – thanking the participants and explaining that the risk feedback 
can be recorded and reviewed at a later time.  
 
INSERT FIGURES 1-3 here 
 
Phase 3: Feasibility of the ORION e-Health tool 
There were no mechanical and/or interpretative issues arising from the field testing stages..  
Satisfactory reports were received on the quality of translation, ease of use of instructions 
and ability to follow the risk estimation procedure. The exploratory field-testing was 
instructive in that it showed the value of the staff member being present to provide 
prompts to navigate the tool and act as an adjunct to the on-screen instructions. 
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We report on the general domains identified as necessary components to a successful tool 
that might help in risk reduction to dysfunctional potentially lethal behaviour. 
1. User involvement. The inclusion of users at the early stage of tool design is crucial to 
attain acceptance and match literacy levels. A balance between ‘house tradition’ and 
matching drug-users preference for ease of use and attractive features needs to be 
considered carefully and with wide consultation. 
 
2. Computer literacy: Drug users comprise individuals from all lifestyles including their 
experiences with computers. Therefore, a further level of difficulty needs to be 
overcome with those who are unfamiliar with information presented on screen. 
Drug users in treatment were found to have poorer computer literacy than other 
matched controls when comparing their skills on seeking employment, 
strengthening the need to design clear and straightforward approaches for engaging 
drug-users in computer assisted health care approaches [48]. The alternative would 
be to enable the drug-user to work alongside a member of staff to assist with the 
process of working with the aid of a computer application. This was the approach 
that was actively introduced with the ORION programme. 
3. Staff training: A neglected area is the attention paid to the training of staff that were 
requested to assist with the delivery of materials such as the ORION software. Not 
only will patients be varied in their interest and competence to make use of 
computer assisted tools but also staff will vary in this respect. Whereas patients may 
feel justified in stating their difficulties it may not be quite so easy for staff to voice 
concerns over the use of such tools for fear of criticism and lack of motivation for a 
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new potentially valuable aid to clinical care. Some evidence suggests that staff were 
aware (50%) that service users do check information about their condition and status 
on the internet but failed to check (24% only) whether the patient consulted online 
information [49].  
 
4. Ethics: Close attention is needed to explore the security of information that has the 
potential to be collected routinely on computer assisted tools. The current system 
devised for ORION was engineered so that all internet capability was removed. This 
somewhat surprising feature was chosen to allow quick and easy access to clinical 
populations for research data collection and gain ethical committee approval in the 
various European Member States where the data were being collected. Question 
responses and additional behavioural data (time spent on screen, key stroke actions 
etc.) were collected through encrypted memory sticks by the research team [50]. 
The support needed for individuals who become aware of the risk of overdose and 
are not part of a treatment environment should also be looked at sensitively. One 
should consider providing the opportunity for individuals to get psychological 
support to potential distress caused by such new information obtained through the 
use of the ORION tool. 
 
5. Ecological validity: Essentially the tool has to perform an important function within 
the assessment, advisory and support role of the drug treatment service.  
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Discussion 
The development of ORION e-health tool underlines the importance of an evidence-based 
intervention aimed in obtaining reliable evaluation of risk. The ORION tool supports a 
decision making process aimed at influencing the substance users’ self-efficacy and the 
degree to which the substance users’ understand risk factors. Therefore its innovative 
power consists in translating risks combination into a clear estimation for the user who will 
appear more likely interested in his/her risk perception.  
We acknowledge several limitations in setting up this e-health tool. The risk estimation 
model used for opioid fatal overdose was derived from published literature. This reduces 
specificity (e.g. local sociodemographic predictors and service user’s drug taking 
behaviours), but increases generalisability based on the rigor of the selected studies. Our 
model shows final point estimates of risk in percentages. This is useful in decision making 
analysis, but these numbers, without confidence intervals, may create a false sense of 
certainty. Finally logistic regression models have their limitations when used to predict 
aberrant behaviour such as fatal overdose events as there is an assumption of implicit 
interactions based upon the initial estimates of risk.  These are mathematical devices for 
inclusion in the algorithm, but clinical data may reveal subsequently more complex 
relationships   
We were not able to collect data that would have given us more information on (1) 
digital/computer literacy, (2) educational status and (3) neuropsychological domains on 
decision making that would have influenced the outcomes of their understanding and 
usability of the ORION tool. This needs further investigation. The ORION tool had the option 
to be used by patient accompanied by their key worker. This approach was used more 
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frequently as the ORION project team did not feel it was important at this stage of the study 
to restrict different methods of conducting this ehealth tool. This collaborative approach 
was seen as an attractive option as it introduced an opportunity to discuss risk perception 
and reduction initiatives possible [51]. Satisfactory reports were received on the quality of 
translation, ease of use of instructions and ability to follow the risk estimation procedure. 
This was assisted by the presence of the staff member to answer questions, or direct 
patients around the screen, especially with those patients who were less competent 
readers. Consequently a version which removes the staff member from the ORION e health 
administration would require additional development in the design to assist with navigation 
prompts as the patient works through the tool’s screens. 
The patients recruited were heterogenous in age and gender with some centres recruiting 
more females and/or older participants. The ORION project did not a priori attempt to 
match populations as it tried to recruit as much as possible a ‘real life ‘ population within 
which the tool could be utilised. However collecting drug use history, severity of opioid 
dependency and recent risky lifestyle behaviours would have provided a better 
understanding of the population studied. This would have contextualised better the 
utilisation to the e-health tool to the risks experienced by the participants. 
Finally the ORION Tool utilised qualitative methodologies. It does not make use of objective 
markers that might shed light to (a) the opioid pharmacokinetics and/or pharmacodynamics, 
which are known to affect addiction potential [52] and (b) opioid pharmacogenetic 
variabilities, which can be involved in increasing the individual probability of fatal outcomes 
with opioid use occurring [53]. In France, a major effort is underway to extend clinical 
pharmacokinetics integrated with pharmacogenetics for quantitative prediction of the effect 
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induced by cytochrome P450 gene polymorphisms in general, and opioid drug dose regimen 
designs [54]. This quantitative approach to opioid dosing has the potential of mitigating 
both addiction potential and fatal outcomes. The approach is underpinned by DDI-Predictor 
(http://www.ddi-predictor.org/) a web-based Bayesian computational database engine 
constructed by the Genophar II Working Group [55]. 
Conclusion 
The overdose risk information (ORION) tool has been designed for ease of use to both 
patients and clinical services.  The pilot implementation of the ORION tool was conducted in 
the four countries to assess the feasibility of tool implementation. Exploratory field testing 
and validation confirmed the next stage of evaluation, namely, collection of routine patient 
samples in study clinics. The associations between risk perception of overdose, engagement 
with the ORION tool and willingness to alter overdose risk factors, in a clinical setting across 
various EU member states will further confirm the ORION tool’s generalisability and 
effectiveness. A practical overdose risk assessment tool for effective implementation in the 
substance misuse field is indicated. The ORION eHealth tool is available for free download at 
http://orion-euproject.com/download-software/. 
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FIGURES 
Figure 1: Overdose Risk Questions 
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Figure 2: Overdose Risk Feedback 
 
 
 
 
 
 
 
 
 
 
 
Page 33 of 37
34 
 
 
Figure 3: Modification of Risk Factors and Estimated Risk of Overdose Relative to Non-Drug User  
 
 
Table 1:  Age and Gender of the Patient Participants by Country 
 UK Germany Italy Denmark Total 
Gender      
Male 29 77 39 7 152 
Female 2 21 1 1 25 
M:F Ratio 14.5 36.7 39 7 6.08 
Age Mean (s.d.) 30.03 (5.39) 40.03 (7.81) 41.90 (8.12) 35.38 (3.78) 38.76 (7.95) 
s.d.= standard deviation 
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Table 2: Estimating Risk of Overdose Relative to Non-Drug User 
Row relriskpercent relrisk100 
1 10 0.34 
2 120 4.03 
3 230 7.72 
4 340 11.41 
5 450 15.10 
6 560 18.79 
7 670 22.48 
8 780 26.17 
9 890 29.87 
10 1000 33.56 
11 1110 37.25 
12 1220 40.94 
13 1330 44.63 
14 1440 48.32 
15 1550 52.01 
16 1660 55.70 
17 1770 59.40 
18 1880 63.09 
19 1990 66.78 
20 2100 70.47 
21 2210 74.16 
22 2320 77.85 
23 2430 81.54 
24 2540 85.23 
25 2650 88.93 
26 2760 92.62 
27 2870 96.31 
28 2980 100.00 
Relriskpercent= relative risk percent 
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Table 3: Factors and Odds Ratio Contributing to Fatal Overdose Risk Estimation Model in Opioid Users: Characteristics of Included Studies 
Aggregate Risk factor  Source Country Size Odds Ratio 
Mixing drugs  
Coffin et al, 2003 USA 7451  
5 Bernstein et al, 2007 USA 8774 
Rome et al, 2008 Scotland 328 
No intervention  
 
Tobin et al, 2005 USA 397  
2 Rome et al, 2008 Scotland 328 
Dietze et al, 2002 Australia 6173 
Mental health  
difficulties  
 
Bohnert et al, 2011 USA 15491  
3 Oliver et al, 2007 England 30 
Gossop et al, 2002 England 1075 
Not receiving 
treatment  
 
 
Clausen et al, 2009 Norway 208  
7 Brugal et al, 2005 Spain 5049 
Fugelstad et al, 1995 Sweden 472 
Davoli et al, 1993 Italy 405  
              2 Injecting  
behaviour  
 
Arendt et al, 2011 Denmark 7996 
Quan et al, 2010 Northern Thailand 314 
Colon et al, 2006 USA 637 
Previous  
overdoses  
 
Cook et al, 1998 Switzerland 190  
2 Stoove et al, 2009 Australia 4884 
Darke et al, 2003 Australia 1033 
Recent (2 weeks) 
release from prison  
 
Ødegård et al, 2010 Norway 338  
 
 
9 
Krinsky et al, 2009 USA 96 
Farrell and Marsden, 2008 England and Wales 48771 
Kariminia et al, 2007 Australia 85203 
Christensen et al, 2006 Denmark 15885 
Bird and Hutchinson, 2003 Scotland 19486 
Seaman et al, 1998 Scotland 316 
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